Rhythm Biosciences has successfully generated the reagents it needs to build its next-generation blood test for colon cancer, ColoSTAT.

Special Report: Colon cancer detector Rhythm Biosciences is yet another step closer to launching its simple and accessible diagnostic tool.

The company (ASX:RHY) says it’s successfully generated reagents — the antibodies and proteins — it needs for the lead biomarkers for its colorectal cancer detecting blood test ColoSTAT.

Rhythm, which listed on the ASX almost one year ago, is developing the blood test to improve the way colon cancer is diagnosed. Recent data indicates that over 850,000 people die from colon cancer each year.

The test uses antibodies to measure the levels of proteins in the blood that vary in the presence or absence of colorectal cancer.

It offers an alternative to the ‘poo-and-post’ faecal test adults receive in the mail when they turn 50, requiring them to send off multiple samples taken over multiple days.

The process can turn many people off and potentially decrease uptake of screening initiatives.

“This is another key milestone completed by Rhythm,” said Rhythm CEO Glenn Gilbert. “Next steps are to scale up the manufacture, optimise these key reagents and integrate them into a robust, reproducible ColoSTAT test. That will be verified in Study 6 which is on track for completion in 2019.”

The long-running reagent project completes this development leg of the process, and Rhythm is now shifting its attention to scaling up manufacturing and assay optimisation.

Rhythm now has seed banks of antibody-producing cell lines for the detection of its lead target biomarkers.

This work provides critical insights into the growth and productivity of these cell lines, information that will be key to informing manufacturing scale up and subsequent optimisation and ongoing development.



Rhythm Biosciences is a Stockhead advertiser.
This advice has been prepared without taking into account your objectives, financial situation or needs. You should, therefore, consider the appropriateness of the advice, in light of your own objectives, financial situation or needs, before acting on the advice. If this advice relates to the acquisition, or possible acquisition, of a particular financial product, the recipient should obtain a disclosure document, a Product Disclosure Statement or an offer document (PDS) relating to the product and consider the PDS before making any decision about whether to acquire the product.